Every 10-Q that SANUWAVE Health, Inc. (SNWV) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SNWV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SNWV filings page.
SANUWAVE Health, Inc. reported Q2 2026 revenue of $9.7 million, down 3% from Q2 2025, and a net loss of $0.7 million versus prior-year net income of $0.6 million. For the first six months of 2026, revenue was $19.4 million, essentially flat year over year, while the net loss narrowed to $2.1 million from $5.6 million.
Gross margin remained high at 76% in Q2 2026 but declined modestly due to lower UltraMIST system volumes and pricing and a mix shift toward consumables. Operating expenses increased across general and administrative, selling and marketing, and research and development, driving an operating loss of $0.3 million for the quarter and $1.4 million year-to-date. Below operating income, total other expense improved sharply, helped by a large reduction in interest expense after a 2025 debt refinancing.
Cash and cash equivalents were $9.4 million at June 30, 2026, with $18.7 million outstanding on a secured term loan and $0.7 million drawn on a revolving credit facility; operating activities generated $0.8 million of cash in the first half. The company has accrued $4.5 million for state and local sales taxes, interest, and penalties and is resolving these exposures through voluntary disclosure agreements. Disclosure controls and internal control over financial reporting remained ineffective due to previously identified material weaknesses in accounting resources, revenue recognition and sales tax processes, and information technology controls, with remediation efforts ongoing.
Sanuwave Health, Inc. reports Q1 2026 results with revenue of $9.6 million, up 3% from Q1 2025, driven mainly by higher UltraMIST consumable volumes despite lower pricing. Gross margin was 77%, but higher operating expenses led to an operating loss of $1.1 million versus prior-year operating income.
Net loss narrowed to $1.4 million from $6.1 million, largely because a prior-year $4.9 million non‑cash loss on derivative liabilities did not recur and interest expense declined. EBITDA was a loss of $0.6 million, while Adjusted EBITDA was positive $1.1 million.
The company ended the quarter with $10.8 million in cash and cash equivalents, $20.1 million outstanding on its Term Loan and $0.7 million drawn on its Revolver, and believes current resources and credit availability can fund operations and debt service for at least twelve months. Management restated Q1 2025 results for sales tax and warranty accounting and continues to report material weaknesses in internal control over financial reporting, with a remediation plan in progress.
SANUWAVE Health (SNWV) reported Q3 2025 results with revenue of $11.5M (up 22% year over year) and gross margin of 78%. Operating income was $1.5M. Net income reached $10.3M, driven by a $6.1M favorable change in warrant fair value and $5.0M other income from a patent sale.
Year to date, revenue was $31.0M (up 39%) and operating income was $4.3M. Consumables and parts contributed $7.0M in the quarter; system revenue was $4.4M. Stock‑based compensation totaled $1.4M in Q3.
Balance sheet and liquidity: SANUWAVE closed a new credit agreement with a $23.0M secured term loan (maturing 2029) and a $5.0M revolver (undrawn availability $4.3M as of Sept 30, 2025), and repaid prior senior secured debt. Management states that refinancing and positive operating income alleviated prior going‑concern doubt. Cash was $9.6M; total liabilities were $38.5M. Shares outstanding were 8,576,164 as of Nov 3, 2025.